OPSENS APPOINTS PAT MACKIN TO ITS BOARD OF DIRECTORS
Quebec City, Quebec, September 7, 2016 – Opsens Inc. (“Opsens”) (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce the appointment of Mr Pat Mackin as a Director of the Company.
“We are delighted to see Pat, a renowned leader in the medical device industry, join us. His expertise as head of leading companies in the cardiovascular space will be valuable as we step up from limited market release to a wider one,” said Louis Laflamme, President and CEO of Opsens.
Pat Mackin brings over 25 years of experience in the medical device industry. Since September 2014, Mr Mackin has been President and Chief Executive Officer of CryoLife, Inc. (NYSE:CRY) (“CryoLife”), a leader in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac surgical procedures. CryoLife markets and sells products in more than 80 countries worldwide.
Before joining CryoLife, he was President of the Cardiac Rhythm Disease Management Division at Medtronic, Inc. (NYSE:MDT) (“Medtronic”). Previously, also at Medtronic, he held the positions of Vice President, Vascular, Western Europe where he launched the Company’s first drug-eluding stent called “Endeavour” and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic, Mr Mackin worked for six years at Genzyme, Inc. serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr Mackin spent five years at Deknatel/Snowden-Pencer, Inc. in various sales and marketing roles and three years as an Officer in the U.S. Army. Mr Mackin received an MBA from the Kellogg Graduate School of Management at Northwestern University and is a graduate of the U.S. Military Academy at West Point.
GRANT OF STOCK OPTIONS
On September 7, 2016, Opsens’ Board of Directors approved the grant of 100,000 stock options to Pat Mackin, pursuant to Opsens’ Stock Option Plan adopted by shareholders on January 18, 2016.
Under the provisions of Opsens’ stock option plan, each stock option granted entitles the holder to subscribe to one Opsens’ common share at the latest on September 6, 2021 at a price of $1.50 per share. The stock options granted allow the holder to subscribe immediately for common stock of Opsens.
About Opsens Inc. (www.opsens.com or www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications, such as the monitoring of oil wells and other demanding industrial applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Thierry Dumas, CPA, CA, Chief Financial Officer, 418.781.0333
Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333